Amendment Flag
Current Fiscal Year End Date
Document Period End Date
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Filer Category
Entity Public Float
Entity Registrant Name
Entity Central Index Key
Entity Common Stock, Shares Outstanding
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Type
Area of land in Lansing, Michigan
Award Type [Axis]
Summary of significant accounting policies [Abstract]
Accounts Receivable [Member]
Billing Status, Type [Axis]
Accounts payable
Accounts Payable, Current
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net
Unbilled accounts receivable
Significant customers and accounts receivable [Abstract]
Accrued expenses and other current liabilities
Less: Accumulated depreciation and amortization
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Accumulated Other Comprehensive Loss [Member]
Accumulated other comprehensive loss
Intangible assets, weighted average useful life
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life
Additional paid-in capital
Additional Paid-in Capital [Member]
Accumulated Amortization [Abstract]
Adjustments to reconcile to net cash provided by operating activities:
All Other [Member]
Total stock-based compensation expense
Allocated Share-based Compensation Expense
Amortization of debt issuance costs, net of tax
Amortization
Amortization of Intangible Assets
Antidilutive Securities [Axis]
Antidilutive shares excluded from calculation (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities, Name [Domain]
Impairment related to equipment
Assets [Abstract]
Assets, Fair Value Disclosure [Abstract]
Total assets
Total assets
Long-lived assets
Total assets of discontinued operations
Disposal Group, Including Discontinued Operation, Assets
ASSETS
Assets [Abstract]
Assets [Abstract]
Disposal Group, Including Discontinued Operation, Assets [Abstract]
Current assets of discontinued operations
Current assets of discontinued operations
Disposal Group, Including Discontinued Operation, Assets, Current
Total assets
Assets, Fair Value Disclosure
Current assets:
Total current assets
Assets, Current
Billed [Member]
Buildings [Member]
Building [Member]
Buildings, Building Improvements and Leasehold Improvements [Member]
Building Improvements [Member]
Building Improvements [Member]
Fair value adjustment for contingent obligations
Purchases of property, plant and equipment unpaid at year end
Amortization of capitalized software
Capitalized Software Development Costs
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Cash and Cash Equivalents, Policy [Policy Text Block]
Net (decrease) increase in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Investment in money market funds
Cash and Cash Equivalents, Fair Value Disclosure
Net cash provided by (used in) financing activities
Cash Provided by (Used in) Financing Activities, Discontinued Operations
Net cash provided by investing activities
Net cash (used in) provided by operating activities
Cash Provided by (Used in) Operating Activities, Discontinued Operations
Senior Managment [Member]
Purchase commitment
Commitments and contingencies
Litigation [Abstract]
$0.001 Par Value Common Stock [Member]
Common Stock [Member]
Common stock, shares issued (in shares)
Common stock, voting rights
Common stock, shares authorized (in shares)
Common stock, $0.001 par value; 200,000,000 shares authorized, 40,996,890 shares issued and 40,574,060 shares outstanding at December 31, 2016; 100,000,000 shares authorized, 39,829,408 shares issued and 39,406,578 shares outstanding at December 31, 2015
Common stock, par value (in dollars per share)
Balance (in shares)
Balance (in shares)
Common stock, shares outstanding (in shares)
Common stock
401(k) savings plan [Abstract]
Significant components of provision for income taxes attributable to operations [Abstract]
Net deferred tax asset [Abstract]
Comprehensive income
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Comprehensive income
Software [Member]
Concentration Risk Benchmark [Axis]
Concentration Risk Type [Axis]
Concentration Risk [Line Items]
Concentrations of credit risk
Concentration Risk Benchmark [Domain]
Concentration Risk [Table]
Concentration Risk Type [Domain]
Concentration risk percentage
Concentration Risk, Percentage
Basis of presentation and consolidation
Consolidation Items [Axis]
Consolidation Items [Domain]
Construction-in-progress [Member]
Contracts and grants
Cost of product sales and contract manufacturing
Cost of Product Sales [Member]
Cost of Sales [Member]
Total current
Current Income Tax Expense (Benefit)
International
State
Current
Federal
U.S. Government [Member]
Long-Term Debt [Line Items]
Debt Instrument [Line Items]
Conversion price per share (in dollars per share)
Long-term debt [Abstract]
Schedule of Long-term Debt Instruments [Table]
Long-term debt
Debt and Capital Leases Disclosures [Text Block]
Debt Instrument [Axis]
Debt Instrument [Axis]
Face amount of debt instrument
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
Interest rate percentage
Maturity date
Intangible assets
Deferred Tax Assets, Goodwill and Intangible Assets
Federal
Deferred Federal Income Tax Expense (Benefit)
Debt issuance costs
International
Deferred Foreign Income Tax Expense (Benefit)
Short-term deferred revenue
Deferred Revenue, Current
Deferred income taxes
Deferred
Deferred revenue, net of current portion
Deferred tax liability
Deferred Tax Liabilities, Gross
Foreign deferrals
Deferred Tax Assets, Operating Loss Carryforwards, Foreign
Inventory reserves
Net operating loss carryforward (federal)
Deferred tax asset
Deferred Tax Assets, Gross
Net deferred tax asset
Deferred Tax Assets, Net
State
Deferred State and Local Income Tax Expense (Benefit)
Deferred tax assets, net
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent
Deferred tax assets, net
Deferred Tax Assets, Net of Valuation Allowance, Current
Stock compensation
Research and development carryforward
Other
Deferred tax liability, net of current portion
Deferred Tax Liabilities, Net, Noncurrent
Other
Deferred Tax Liabilities, Other
Deferred tax liability, net
Intangible assets
Deferred Tax Liabilities, Intangible Assets
Fixed assets
Deferred Tax Liabilities, Property, Plant and Equipment
Valuation allowance
Deferred Tax Assets, Valuation Allowance
Matching of qualified deferrals by employer, maximum
Matching contributions made by employer
Depreciation and amortization
Income (loss) from discontinued operations before provision for (benefit from) income taxes
Discontinued operations [Abstract]
Net loss per share from discontinued operations-diluted (in dollars per share)
Net loss per share from discontinued operations-diluted
Net loss per share from discontinued operations-basic
Held-for-sale [Member]
Disposed of by Sale [Member]
TSA revenue from Aptevo
Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Revenue
Net Income (loss) from discontinued operations
Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax
Provision for (benefit from) income taxes
Discontinued Operation, Tax (Expense) Benefit from Provision for (Gain) Loss on Disposal
Net loss per share from discontinued operations-basic (in dollars per share)
Net loss from discontinued operations-basic
Net loss from discontinued operations-basic
Cost of product sales
Prepaid expenses and other current assets
Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current
Goodwill
Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent
Total revenues
Disposal Group, Including Discontinued Operation, Revenue
Disposal Group Classification [Domain]
Deferred revenue, net of current portion
Disposal Group, Including Discontinued Operation, Deferred Revenue, Noncurrent
Accounts payable
Disposal Group, Including Discontinued Operation, Accounts Payable, Current
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]
Other liabilities
Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent
Cash and cash equivalents
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents
Other current assets
Income (loss) from operations
Disposal Group, Including Discontinued Operation, Operating Income (Loss)
Disposal Group Classification [Axis]
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Property, plant and equipment, net
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent
Non-current assets of discontinued operations
Non-current assets of discontinued operations
Deferred revenue, current portion
Disposal Group, Including Discontinued Operation, Deferred Revenue, Current
Accrued compensation
Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current
Intangible assets, net
Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent
Inventories
Disposal Group, Including Discontinued Operation, Inventory, Current
Accounts receivable, net
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net
Disposal Group Name [Domain]
Discontinued operations
Net income per share - basic:
Net income per share - diluted:
Earnings Per Share
Net income per share - basic (in dollars per share)
Earnings Per Share, Basic
Net income per share-diluted
Earnings Per Share, Diluted
Earnings per share
Earnings Per Share [Text Block]
Earnings per share [Abstract]
Effect of exchange rate changes on cash and cash equivalents
Effective annual tax rate
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Accrued compensation
Employee-related Liabilities, Current
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition
Stock Options [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options
Equity Component [Domain]
Excess tax benefits from stock-based compensation
Excess tax benefits from stock-based compensation
Excess Tax Benefit from Share-based Compensation, Operating Activities
Additions
Fair value of measurements
Fair Value, Hierarchy [Axis]
Measurement Frequency [Axis]
Fair value measurements [Abstract]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance, beginning of period
Balance, end of period
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Fair Value Hierarchy [Domain]
Transfers in/(out) of Level 3
Settlements
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Fair value measurements
Fair Value Disclosures [Text Block]
Fair Value, Inputs, Level 3 [Member]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Unobservable Input Reconciliation [Roll Forward]
Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)
Expense (income) included in earnings
Finite-Lived Intangible Assets by Major Class [Axis]
2018
Finite-Lived Intangible Assets, Amortization Expense, Year Two
Net book value of intangible assets
Finite-Lived Intangible Assets, Net
Accumulated Amortization, Beginning Balance
Accumulated Amortization, Ending balance
Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2017
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months
Intangible Assets, Beginning Balance
Intangible Assets, Ending Balance
Finite-Lived Intangible Assets, Gross
Finite-Lived Intangible Assets, Major Class Name [Domain]
2020
Finite-Lived Intangible Assets, Amortization Expense, Year Four
2019
Finite-Lived Intangible Assets, Amortization Expense, Year Three
Foreign currencies
United Kingdom Tax Authority [Member]
Foreign Tax Authority [Member]
Furniture and Equipment [Member]
Furniture and Fixtures [Member]
United States [Member]
Goodwill, Beginning Balance
Goodwill, Ending Balance
Goodwill, Gross
Goodwill
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Goodwill, net book value
Goodwill
Goodwill [Roll Forward]
Intangible assets, in-process research and development
Goodwill, Additions
Goodwill, Acquired During Period
Intangible assets and in-process research and development [Abstract]
Income from operations
Intersegment Eliminations [Member]
Impairment of long-lived assets
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Impairment and abandonment of long-lived assets
Impairment of idled equipment
Impairment of in-process research and development
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Mergers and Acquisitions
In Process Research and Development, Policy [Policy Text Block]
Income taxes [Abstract]
Earnings before taxes on income
Income (Loss), Including Portion Attributable to Noncontrolling Interest
Federal income tax year selected for audit
Net income from continuing operations-basic
Net income per share - basic from continuing operations (in dollars per share)
Net income per share from continuing operations-basic (in dollars per share)
Income Statement Location [Axis]
Income Statement Location [Axis]
International
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Income from continuing operations before provision for income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Income Statement Location [Domain]
Income (loss) from discontinued operations
Loss from discontinued operations (net of tax)
Income Tax Authority [Axis]
Income Tax Authority [Axis]
US
Net income per share from continuing operations-diluted
Net income per share from continuing operations-diluted (in dollars per share)
Net income per share - diluted from continuing operations (in dollars per share)
Income Tax Authority [Domain]
Income Tax Authority [Domain]
Income taxes
Income Tax Disclosure [Text Block]
Provision for income taxes
Total provision for income taxes
Income Tax Contingency [Table]
Consolidated Statements of Operations [Abstract]
Disposal Groups, Including Discontinued Operations [Table]
Income Tax Contingency [Line Items]
Disposal Group Name [Axis]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Federal tax at statutory rates
Income tax reconciliation [Abstract]
Permanent differences
Change in valuation allowance
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Impact of foreign operations
Other differences
Effect of foreign rates
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount
Income tax receivable, net
Tax credits
Effective Income Tax Rate Reconciliation, Tax Credit, Amount
Income taxes
State taxes, net of federal benefit
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount
Cash paid during the year for income taxes
Net income from continuing operations
Net Income from continuing operations
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Accounts payable
Accounts receivable
Increase (Decrease) in Accounts Receivable
Accrued expenses and other liabilities
Inventories
Increase (Decrease) in Inventories
Deferred revenue
Increase (Decrease) in Deferred Revenue
Income taxes
Increase (Decrease) in Income Taxes Receivable
Accrued compensation
Changes in operating assets and liabilities:
Increase in unbilled accounts receivable
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Dilutive securities-equity awards (in shares)
Dilutive securities-convertible debt
Intangible Assets [Abstract]
Cost Basis [Abstract]
Intangible assets
Intangible assets, net
Intangible Assets, Net (Excluding Goodwill)
Capitalized interest
Interest Capitalization, Policy [Policy Text Block]
Interest expense
Interest Expense
Capitalized interest [Abstract]
Interest costs capitalized
Interest costs incurred
Interest expense, net of tax
Cash paid during the year for interest
U.S. Federal Tax Authority [Member]
Internal Revenue Service (IRS) [Member]
Inventories
Inventories
Total inventories
Inventory, Net
Finished goods
Inventories
Inventory Disclosure [Text Block]
Inventories [Abstract]
Work-in-process
Raw materials and supplies
Interest income
Interest revenue
Land and Improvements [Member]
Leasehold Improvements [Member]
Litigation
Total liabilities
Liabilities
Non-current liabilities of discontinued operations
Non-current liabilities of discontinued operations
Current liabilities of discontinued operations
Current liabilities of discontinued operations
Total liabilities of discontinued operations
Disposal Group, Including Discontinued Operation, Liabilities
Liabilities [Abstract]
Disposal Group, Including Discontinued Operation, Liabilities [Abstract]
Total liabilities and stockholders' equity
Liabilities and Equity
LIABILITIES AND STOCKHOLDERS' EQUITY
Total liabilities
Financial and Nonfinancial Liabilities, Fair Value Disclosure
Liabilities [Abstract]
Liabilities, Fair Value Disclosure [Abstract]
Total current liabilities
Liabilities, Current
Current liabilities:
Maximum borrowing capacity
Line of Credit Facility, Maximum Borrowing Capacity
Accounts receivable
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]
Long-term indebtedness, current portion
Long-term indebtedness, net of current portion
Long-term Debt, Excluding Current Maturities
Significant customers and accounts receivable
Maximum [Member]
Minimum [Member]
Noncontrolling interest in subsidiaries
Nature of the business and organization
Nature of Operations [Text Block]
Cash flows from financing activities:
Net increase in cash and cash equivalents
Net Cash Provided by (Used in) Discontinued Operations
Net Cash Provided by (Used in) Discontinued Operations [Abstract]
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Cash flows from operating activities:
Net cash (used in) provided by financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations
Net cash provided by operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Cash flows from investing activities:
Net income
Net income
Net income
Numerator [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Net loss attributable to noncontrolling interest
Recently issued and adopted accounting standards
Total other income (expense)
Nonoperating Income (Expense)
Other income (expense):
Notes payable, current portion
Number of business segments
Noncontrolling Interest in Subsidiary [Member]
Open tax year
Operating expenses:
Operating Segments [Member]
Operating Loss Carryforwards [Table]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards
Income from operations
Operating Income (Loss)
Operating loss carryforwards, expiration year
Nature of the business and organization [Abstract]
Foreign currency translations, net of tax
Foreign currency translations, net of tax
Reclassification of cumulative currency translation adjustment to income, net of tax
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax
Other
Other Noncash Income (Expense)
Other Costs [Member]
Other assets
Other Depreciation and Amortization
Non-cash development expenses from joint venture
Supplemental information on non-cash investing and financing activities:
Other income (expense), net
Other liabilities
Products and Services [Domain]
Amount paid
Payments for Restructuring
Acquisitions, net of acquired cash
Payments to Acquire Businesses, Net of Cash Acquired
Purchase of treasury stock
Payments for Repurchase of Common Stock
Expenditures for long-lived assets
Purchases of property, plant and equipment
Payments to Acquire Property, Plant, and Equipment
401(k) savings plan
Pension and Other Postretirement Benefits Disclosure [Text Block]
Plan Name [Domain]
Plan Name [Axis]
Preferred stock, shares issued (in shares)
Preferred stock
Preferred stock, shares authorized (in shares)
Preferred stock, par value (in dollars per share)
Preferred stock, shares outstanding (in shares)
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at both December 31, 2016 and December 31, 2015
Prepaid expenses and other current assets
Proceeds from sale of assets
Restricted cash deposit
Proceeds from convertible debenture, net of bank fees
Proceeds from Convertible Debt
Proceeds from borrowings on long-term indebtedness
Proceeds from Issuance of Long-term Debt
Proceeds from maturity of investments
Issuance of common stock subject to employee equity plans
Products and Services [Axis]
Net income
Net income (loss)
Estimated useful lives
Property, Plant and Equipment, Type [Domain]
Property, plant and equipment [Abstract]
Property, plant and equipment
Estimated useful lives
Property, Plant and Equipment, Estimated Useful Lives
Property, plant and equipment
Property, Plant and Equipment [Table Text Block]
Property, plant and equipment, net
Total Property, plant and equipment, net
Property, Plant and Equipment [Line Items]
Property, plant and equipment
Property, Plant and Equipment, Gross
Property, Plant and Equipment, Type [Axis]
Property, plant and equipment
Property, Plant and Equipment Disclosure [Text Block]
Bad debt expense
Total purchase commitment to Norwood Laboratories Inc.
Quarterly financial data (unaudited)
Quarterly Financial Information [Text Block]
Quarterly financial data (unaudited) [Abstract]
Range [Axis]
Range [Domain]
Accounts receivable [Abstract]
Receivables Billing Status [Domain]
Gross unrecognized tax benefits activity [Roll Forward]
Percentage of net sales of biodefense products subject to payment to related party
Related party transactions
Related Party Transactions Disclosure [Text Block]
Related Party [Domain]
Costs incurred from services rendered under marketing/consulting agreement
Related Party Transaction [Line Items]
Related Party [Axis]
Related party transactions [Abstract]
Principal payments on long-term indebtedness and line of credit
Payments on borrowings on long-term indebtedness
Repayments of Long-term Debt
Research and development
Research and Development [Member]
Research and Development Expense [Member]
Research and Development Tax Credit [Member]
Research and development
Research and Development Expense, Policy [Policy Text Block]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units (RSUs) [Member]
Restricted Cash
Restricted Cash and Cash Equivalents
Restricted cash [Abstract]
Restricted Cash and Investments [Abstract]
Expenses incurred
Restructuring Charges
Balance, end of period
Balance, beginning of period
Restructuring Reserve
Restructuring Plan [Domain]
Restructuring Plan [Axis]
Incurred in 2016
Restructuring [Abstract]
Summary of activity for liabilities [Roll Forward]
Restructuring Type [Axis]
Total Expected to be Incurred
Restructuring Cost and Reserve [Line Items]
Restructuring
Other adjustments
Retained Earnings [Member]
Retained earnings
Revenue recognition [Abstract]
Revenue recognition
External revenue
Revenues
Subsegments [Axis]
Subsegments [Domain]
Exercisable, beginning of period
Exercisable, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Aggregate intrinsic value [Abstract]
Contractual life of awards
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period
Weighted average remaining contractual term of options outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted average remaining contractual term of options exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Outstanding, beginning of period
Outstanding, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
Expected average life of options
Future Amortization Expense
Revenues:
Total revenues
Revenue
Product sales
Revenues [Member]
Sales Revenue, Goods, Net [Member]
Revenue [Member]
Inventories
Schedule of Inventory, Current [Table Text Block]
Components of the provision for income taxes attributable to operations
Net deferred tax asset
Restricted stock units activity
Option award activity
Intangible Assets
Assumptions used in valuing stock options granted
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Gross unrecognized tax benefits activity
Summary of basic and diluted net income per share
Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Quarterly financial information
Reconciliation of taxes determined by applying U.S. federal statutory rate to loss before provision for income taxes
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Goodwill
Schedule of Goodwill [Table Text Block]
Allocated stock-based compensation expense
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]
Property, Plant and Equipment [Table]
Schedule of Restructuring and Related Costs [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Costs of the restructuring
Summary of the activity for liabilities related to EPDU restructuring
Schedule of Accounts, Notes, Loans and Financing Receivable [Table]
Accounts receivable
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
Segment information
Segment Reporting Disclosure [Text Block]
Segments [Domain]
Segments [Domain]
Segment information [Abstract]
Segment Reporting Information [Line Items]
Geographical [Domain]
Geographical [Domain]
Continuing Operations [Member]
Discontinued Operations [Member]
Operating Activities [Domain]
Selling, general and administrative
Selling, General and Administrative Expense
Selling, General and Administrative [Member]
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense
Granted (in dollars per share)
Share Repurchase Program [Axis]
Share Repurchase Program [Domain]
Forfeited (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Weighted-Average Grant Price [Roll Forward]
Exercised (in dollars per share)
Granted (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Discount from market price
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date
Restricted stock unit award activity [Roll Forward]
Cancelled (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares of common stock available for issuance (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Forfeited (in dollars per share)
Maximum number of shares that may be granted per year to a single participant (in shares)
Maximum number of shares that may be granted per year to a single participant (in shares)
Equitable adjustment (in dollars per share)
Weighted-Average Exercise Price [Roll Forward]
Granted (in shares)
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Cancelled (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Outstanding, end of period (in dollars per share)
Outstanding, beginning of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Outstanding, beginning of period (in shares)
Outstanding, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Exercisable, beginning of period (in dollars per share)
Exercisable, end of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Common stock authorized for issuance under the plan (in shares)
Risk-free interest rate
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Employee subscription rate
Exercisable, end of period (in shares)
Exercisable, beginning of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Aggregate Intrinsic Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Total intrinsic value of options exercised
Vested (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Vested (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Assumptions used in valuing the stock options granted [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected dividend yield
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Common stock available for future awards (in shares)
Expected volatility
Outstanding, end of period (in dollars per share)
Outstanding, beginning of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Options expected to vest, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Outstanding, beginning of period (in shares)
Outstanding, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Options expected to vest, end of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Options expected to vest, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Award Type [Domain]
Outstanding, end of period
Outstanding, beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Options outstanding [Roll Forward]
Equitable adjustment (in shares)
Weighted average grant date fair value of options granted (in dollars per share)
Accounting for stock-based compensation
Summary of significant accounting policies
Significant Accounting Policies [Text Block]
Termination Benefits [Member]
State and Local Jurisdiction [Member]
Statement [Line Items]
Equity Components [Axis]
Equity Components [Axis]
Consolidated Statement of Changes in Stockholders' Equity [Abstract]
Consolidated Statements of Cash Flows [Abstract]
Consolidated Statements of Comprehensive Income [Abstract]
Statement [Table]
Operating Activities [Axis]
Consolidated Balance Sheets [Abstract]
Segments [Axis]
Segments [Axis]
Geographical [Axis]
Issuance of stock for the Trubion Pharmaceuticals, Inc. acquisition (in shares)
Stock repurchased as part of stock swap (in shares)
Employee equity award plans activity (in shares)
Stock Repurchase Program, Authorized Amount
Treasury stock (in shares)
Stock Repurchased During Period, Shares
Outstanding Stock Awards [Member]
Treasury stock
Stock Repurchased During Period, Value
Issuance of stock for the Trubion Pharmaceuticals, Inc. acquisition
Exercised (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Employee equity award plans activity
Stockholders' equity:
Separation of Aptevo
Total stockholders' equity
Balance
Balance
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Stockholders' equity
Stockholders' equity [Abstract]
Total Emergent BioSolutions Inc. stockholders' equity
Stockholders' Equity Attributable to Parent
Supplemental disclosure of cash flow information:
Tax Credit Carryforward, Name [Domain]
Tax Credit Carryforward [Axis]
Tax credit carryforwards, expiration date
Tax Credit Carryforward, Expiration Date
Tax Credit Carryforward [Table]
Tax credit carryforward, amount
Tax Credit Carryforward [Line Items]
Income tax payable, net
Taxes Payable, Current
Treasury Stock [Member]
Treasury stock (in shares)
Treasury stock, at cost, 422,830 common shares at both December 31, 2016 and December 31, 2015
Treasury Stock, Value
Type of Restructuring [Domain]
Unbilled [Member]
Increases for tax positions for prior years
Increases for tax positions for current year
Settlements
Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities
Lapse of statute of limitations
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Accrued interest and penalties related to unrecognized tax benefits
Gross unrecognized tax benefits, beginning balance
Gross unrecognized tax benefits, ending balance
Unrecognized Tax Benefits
Decreases for tax positions for prior years
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Unsecured debt
Unsecured Debt
Use of estimates
Weighted-average number of shares - diluted (in shares)
Weighted-average number of shares-diluted (in shares)
Denominator [Abstract]
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted-average number of shares - basic (in shares)
Weighted-average number of shares-basic (in shares)
United Arab Emirates [Member]
Qatar [Member]
Saudi Arabia [Member]
Revenue earned during the period arising from manufacturing sale under the terms of a contract.
Contract manufacturing
Number of business units under the entities reporting segments.
Number of business units
Carrying amount of purchased research and development assets acquired in a business combination that have an indefinite life until completion or abandonment of the associated research and development efforts.
In process research and development
In-process research and development assets
In-process research and development
Segment of the Company which develops vaccines, antibody therapies and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs.
Biosciences [Member]
Segment of the Company which develops, manufactures and commercializes vaccines and antibody therapies for use against biological agents that are potential weapons of bioterrorism or biowarfare.
Biodefense [Member]
Refers to foreign jurisdictions.
ForeignJurisdictions [Member]
Foreign Jurisdictions [Member]
Refers to contingent payment that may be received by the entity, upon the achievement of specified development and regulatory milestones.
Contingent payment received based upon development and regulatory milestones
Refers to the number of publicly traded companies into which entity is separated.
Number of Independent Public Traded Entities
Number of independent public companies
The gross amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns, and classified as a non-current liability as of the balance sheet date.
Unrecognized tax benefits, noncurrent
The gross amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns, and classified as a current liability as of the balance sheet date.
Unrecognized tax benefits, current
Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns as of the balance sheet date, which is expected to be reversed within next twelve months.
Unrecognized tax benefits, amount expected to be reversed within next twelve months
Estimated unrecognized tax benefits expected to be reversed within next twelve months
The portion of profit or loss for the period, net of income taxes and other adjustments.
Adjusted net loss
Net income (loss), adjusted
The portion of profit or loss for the period, adjusted from continuing operations.
Net income, adjusted from continuing operations
Net income, adjusted from continuing operations
Period of a change in the nature or conduct of the business following a change in ownership, which changes the life of operating loss carryforwards.
Operating Loss Carryforwards, Period of Change in Nature and Conduct of Business for Changing Life of Operating Loss Carryforwards
Period of change in the nature or conduct of business following change in ownership
The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations before purchase price adjustment.
Deferred Income Tax Expense (Benefit) before purchase price adjustment
Total deferred
Refers to Canadian Federal Scientific Research And Experimental Development.
CanadianFederalScientificResearchAndExperimentalDevelopment [Member]
Canadian Federal Scientific Research And Experimental Development [Member]
Refers to Manitoba Scientific Research And Experimental Development.
ManitobaScientificResearchAndExperimentalDevelopment [Member]
Manitoba Scientific Research And Experimental Development [Member]
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible scientific research and experimental development tax credit carryforwards.
Deferred Tax Assets, Tax Credit Carryforwards, Scientific Research and Experimental Development
Scientific research and experimental development credit carryforward
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Net Operating Loss Carryforward (state)
Refers to State and Local Jurisdiction -Tax Effected.
State and Local Jurisdiction -Tax Effected [Member]
State and Local Jurisdiction - Tax Effected [Member]
Refers to U.S. Federal Tax Authority-Tax Effected.
U.S. Federal Tax Authority-Tax Effected [Member]
U.S. Federal Tax Authority - Tax Effected [Member]
Refers to Canadian Federal Gross.
Canadian Federal Gross [Member]
Refers to Canadian Federal Tax Effected.
Canadian Federal Tax Effected [Member]
Refers to Foreign Tax Authority Tax Effected.
Foreign Tax Authority Tax Effected [Member]
Stock Repurchase Plan of 2012.
Stock Repurchase Plan of 2012 [Member]
Treasury Stock [Abstract]
Amount of purchases, sales, and issuances in relation to liabilities measured at fair value on a recurring basis using unobservable inputs (level 3).
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Sales, Issues
Purchases, sales and issuances
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents a type of right given to shareholders of an acquired company (or a company facing major restructuring) that ensures they receive additional benefit if a specified event occurs.
Contingent Value Rights, Fair Value Disclosure
Contingent price consideration
Business acquisition in December 2014 and December 2015
Evolva Holding SA 035 & Unither [Member]
RSDL, a product of HPPD.
RSDL [Member]
The cash outflow associated with the acquisition of a business' contingent purchase price.
Payment of contingent obligations
Refers to the products RSDL and HepaGam.
RSDL and HepaGam [Member]
Refers to the contingent value rights based on the novation of the contract with an agency.
Contingent value rights based on the novation of the contract
Disclosure of accounting policy for contingent consideration obligations.
Contingent Consideration Obligations [Policy Text Block]
Contingent purchase consideration obligations
Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.
Property, Plant and Equipment Useful Lives [Text Block]
Estimated useful lives of property, plant and equipment
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Cash And Cash Equivalents Continuing Operations
Cash and cash equivalents
Carrying value as of the balance sheet date of the current portion of liabilities incurred and payable to former shareholders and stock option holders of Trubion Pharmaceuticals for certain developmental, regulatory or commercial milestones.
Contingent Value Rights Current Portion
Contingent purchase consideration, current portion
Current portion of the carrying values as of the balance sheet date of obligations incurred through that date and payable for chargebacks.
Provision for chargebacks
Carrying value as of the balance sheet date of the noncurrent portion of liabilities incurred and payable to former shareholders and stock option holders for certain developmental, regulatory or commercial milestones.
Contingent Consideration Net Of Current Portion
Contingent purchase consideration, net of current portion
Amount of cash outflow associated with the distribution of Aptevo common stock.
Distribution of Aptevo
Distribution to Aptevo
Fair value measurement of contingent value rights and contingent purchase considerations granted under purchase agreements.
Change In Fair Value Of Contingent Consideration
Change in fair value of contingent obligations
The cash outflow for contingent value rights.
Contingent value right payment
Contingent obligation payments
Write-off of amounts previously recorded bank fees.
Write off of bank fees
Write off of debt issuance costs
The provision charged to earnings in the period related to chargebacks obligations.
Provision for chargebacks, charged to earnings
Provision for chargebacks
Increase in noncontrolling interest balance because of non-cash development expenses from joint venture.
Noncontrolling Interest, Noncash development expenses from joint venture
Non-cash development expenses from joint venture
Percentage of the employee's gross salary that is subject to employer's matching contribution.
Defined Contribution Plan, Percentage of Employee Gross Salary Subject to Employer Matching
Percentage of employee's gross salary subject to employer's matching contribution
Revolving credit loan dated in December 2013.
Revolving Credit Loan dated December 2013, due in December 2018 [Member]
BAML Revolving Credit Facility [Memeber]
Credit agreement dated December 2013.
Credit Agreement [Member]
Debt instrument dated January 2014 due 2021.
Convertible Senior Notes Due 2021 [Member]
2.875% Convertible Senior Notes Due 2021 [Member]
Refers to the BAML Term Loan.
EBS BAML Term Loan [Member]
BAML Term Loan [Member]
Loan obtained from State of Maryland and Montgomery County.
State of Maryland and Montgomery County [Member]
Maximum senior leverage ratio required to be maintained under a debt covenant agreement. A leverage ratio is calculated by dividing the funded debt by earnings before interest, taxes, depreciation and amortization for the most recent four quarters.
Debt Instrument, covenant, senior leverage ratio
Debt Instrument, covenant, senior leverage ratio, maximum
The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.
Debt Instrument, Number of Equity Instruments
Conversion rate of notes per $1,000 principal amount (in shares)
Number of lending institutions in which the entity has a credit facility.
Number of lending institutions
Minimum cash and liquid investments balance required in order to be in compliance with the covenant clauses of the debt agreement.
Debt instrument covenant, minimum cash and liquid investments balance
Debt covenant, minimum cash and liquid investments balance
A debt coverage ration required to be maintained under a debt covenant agreement. The debt coverage ratio is calculated by dividing earnings before interest, taxes, depreciation and amortization for the most recent four quarters less cash taxes by the sum of current obligations and interest expense for borrowed money, in each case due and payable following four quarters.
Debt Instrument, covenant, debt coverage ratio
Debt covenant, consolidated debt service coverage ratio, minimum
The amount of project costs to be expended at Montgomery County Site.
Project costs to be expended at Montgomery County Site
Project costs to be expended at Montgomery County Site
Maximum leverage ratio required to be maintained under a debt covenant agreement. A leverage ratio is calculated by dividing the funded debt by earnings before interest, taxes, depreciation and amortization for the most recent four quarters.
Debt Instrument, covenant, leverage ratio
Debt covenant, leverage ratio, maximum
Debt issuance costs within prepaid expense and other current assets.
Prepaid expense and other current assets [Member]
Debt issuance costs within other assets.
Other assets -debt issuance costs [Member]
Long term debt, net of debt issuance costs.
Long term debt, net of debt issuance costs [Member]
Amount of debt issuance costs in prepaid and other current assets, netted against long term debt.
Amount of debt issuance costs in prepaid and other current assets, netted against long term debt [Member]
Amount of debt issuance costs in other assets, netted against long term debt.
Amount of debt issuance costs in other assets, netted against long term debt [Member]
Amount of amortization expense expected to be recognized during the fifth fiscal year and after following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
Finite Lived Intangible Assets Amortization Expense Year Five and After
2021 and beyond
A series of molecules included as an IPR&D asset.
EV-035 [Member]
Goodwill, Cost Basis [Abstract]
A component of the Biosciences business segment.
Contract Manufacturing [Member]
A component of the Biodefense segment.
Therapeutics and Vaccines [Member]
A component of the Biodefense segment.
Medical Devices [Member]
Number of doses of FDA-licensed anthrax vaccine to be supplied under a contract.
Number of doses of FDA licensed anthrax vaccine to be supplied under contract
Number of doses of BioThrax to be supplied under contract
Percentage of total spending in collaboration used to determine the receivable, revenue, payable and expense during period.
Percentage of total spending in collaboration used to determine the receivable, revenue, payable and expense during period
Percentage of total spending in collaboration used to determine the receivable, revenue, payable and expense during period
A share-based compensation plan adopted by the Company in 2006.
Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]
2006 Plan [Member]
Period during which the contractual agreement is effective.
Period of contractual agreement
Minimum exercise price of option as percentage of the fair market value of the shares underlying such option on the date of grant.
Exercise price of option as percentage of fair market value at grant date, minimum
Exercise price of option as percentage of fair market value at grant date, minimum
Represents the number of shares of common stock available for issuance under the 2006 Plan for each restricted stock unit granted.
Restricted stock unit conversion ratio
Restricted stock unit conversion ratio
Represents the period over which options can be exercised from the date of grant.
Share Based Compensation Arrangement by share Based Payment Award, Options, Exercise Period
Exercise period of options, maximum
Represents the number of stock-based compensation plans the company maintains.
Number of stock based employee compensation plans
Number of stock based employee compensation plans
Refers to the Company's two stock-based employee compensation plans, the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan").
Emergent Plans [Member]
A share-based compensation plan adopted by the Company in 2004.
Emergent BioSolutions Employee Stock Option Plan [Member]
2004 Plan [Member]
Document and Entity Information [Abstract]
Represents the Company's 2012 Employee Stock Purchase Plan.
Employee Stock Purchase Plan [Member]
Represents the percentage of the threshold limit for common stock ownership to be ineligible to participate in ESPP.
Employee Stock Purchase Plan, Threshold limit for common stock ownership to be ineligible to participate in ESPP, Percentage
Threshold limit for common stock ownership to be ineligible to participate in ESPP
Represents the number of plan periods for ESPP.
Employee Stock Purchase Plan, Number of plan periods
Number of plan periods
Fair value of share-based compensation awards vested. Includes options, share units, stock appreciation rights, and restricted stock.
Share based Compensation Arrangement Share based Payment Award, Awards Vested in Period, Fair Value
Total fair value of awards vested
The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period
Cancelled (in shares)
Equitable adjustment of shares (or other type of equity) under an equity-based award plan, other than a stock option plan during the reporting period.
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Other Increases (Decreases) in Period
Equitable adjustment (in shares)
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that expired during the reporting period.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Grant Date Fair Value
Cancelled (in dollars per share)
Equitable adjustment of weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans during the reporting period.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Equitable Adjustment Weighted Average Grant Date Fair Value
Equitable adjustment (in dollars per share)
Purchase commitment [Abstract]
Raw materials related to the Company's RSDL product purchased from Norwood.
NorwoodLaboratoriesPurchase
Materials purchased from Norwood Laboratories Inc as of December 31, 2014
Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
Schedule Of Disposal Groups Including Discontinued Operations Cash Flow [Table Text Block]
Summary of disposal groups including discontinued operations cash flows
Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
Schedule Of Disposal Groups Including Discontinued Operations Balance Sheet [Table Text Block]
Summarized results of discontinued operations included in consolidated statements of income
Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
Schedule Of Disposal Groups Including Discontinued Operations Income Statement [Table Text Block]
Summary of assets and liabilities presented as discontinued operations
Number of shares received by shareholders due to spin-off.
Number of shares received (in shares)
Number of shares held as of the record date of the spin-off.
Number of shares held (in shares)
Amount classified as notes receivable attributable to disposal group held for sale or disposed of.
Disposal Group, Including Discontinued Operation, Notes Receivable, Net
Notes receivable
Record Date
Record date for distribution
Record date for distribution
Percentage Of Outstanding Shares Distributed
Percentage Of Outstanding Shares Distributed
Percentage of outstanding shares distributed
Disposal Group Not Discontinued Operation Income Statement Sales Revenue [Abstract]
Revenues [Abstract]
Disposal Group Including Discontinued Operation Nonoperating Income Expense [Abstract]
Other income (expense), net [Abstract]
Disposal Group Including Discontinued Operation Operating Expenses [Abstract]
Operating expense [Abstract]
Amount of selling, general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.
Disposal Group Including Discontinued Operation Selling General And Administrative Expense
Selling, general and administrative
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts attributable to disposal group, including but not limited to, discontinued operations.
Disposal Group Including Discontinued Operation Sales Revenue Goods Net
Product sales
Disposal Group, Including Discontinued Operation, Other Income (Expense), Net
Disposal Group Including Discontinued Operation Other Income (Expense) Net
Other income (expense), net
Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other attributable to disposal group, including, but not limited to, discontinued operation.
Disposal Group Including Discontinued Operation Contracts Revenue
Contracts, grants and collaborations
Shares issued in the distribution.
Number of common stock distributed
Number of common stock distributed (in shares)
Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation.
Disposal Group Including Discontinued Operation Research And Development
Research and development
Term for additional funding following the distribution.
Term for additional funding
Amount classified as in process research and development attributable to disposal group held for sale or disposed of.
Disposal Group Including Discontinued Operation In Process Research And Development
In-process research and development
Term of manufacturing services contract commencing on the date of distribution.
Term of manufacturing services contract
Amount classified as accrued expenses and other current liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
Disposal Group Including Discontinued Operation Accrued Expenses And Other Current Liabilities
Accrued expenses and other current liabilities
Amount classified as contingent consideration attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
Disposal Group Including Discontinued Operation Contingent Consideration Current
Contingent consideration, current portion
Term of agreement to provide transitional services following the date of distribution.
Term of transition services agreement
Company which develops vaccines, antibody therapies and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs.
Aptevo [Member]
Aptevo [Member]
Amount of expense related to write down of receivables to the amount expected to be collected attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
Disposal Group Including Discontinued Operation Provision For Chargebacks
Provision for chargebacks
Amount of revenue from manufacturing services.
Manufacturing services revenue
Restructuring costs related to retention of certain employees.
Retention Payments [Member]
A plan adopted by the Company in August 2016 to restructure and reprioritize the operations of Emergent BioDefense Operations Lansing LLC ("EBOL").
EBOL Restructuring Plan [Member]
Restructuring cost related to abandonment of equipment.
Abandonment of Equipment [Member]
Cumulative amount of costs incurred from inception to date for the specified restructuring cost.
Restructuring And Related Cost Cost Incurred Inception To Date
Inception to Date Costs Incurred